Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$0.39
-0.3%
$0.38
$0.30
$3.33
$9.08M-1.37166,867 shs152,801 shs
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$1.81
+4.3%
$1.72
$1.41
$5.01
$9.98M1.1822,532 shs91,786 shs
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$3.04
+1.2%
$3.01
$2.51
$5.55
$9.24M-0.6730,702 shs6,341 shs
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
$0.09
-44.6%
$0.00
$0.09
$2.48
$2.45M0.942.28 million shs14.57 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-1.52%-5.60%-7.40%-43.44%-84.54%
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
+0.58%+8.12%-1.14%-30.80%-65.19%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
+1.35%-3.69%-9.09%-10.45%-37.87%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
0.00%0.00%-55.19%+9,409,900.00%+9,409,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
2.1404 of 5 stars
3.53.00.00.02.61.70.0
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.4818 of 5 stars
3.54.00.00.03.22.51.3
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
3.351 of 5 stars
3.85.00.00.02.91.70.6
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
3.00
Buy$8.001,956.56% Upside
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.00
Buy$15.50773.24% Upside
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
3.50
Strong Buy$10.00232.78% Upside
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PTN, ACXP, KPRX, and APRE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$8.00
3/28/2025
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/25/2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
3/19/2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/A$0.34 per shareN/A
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$580K16.93N/AN/A$4.54 per share0.39
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$16M0.57N/AN/A$7.14 per share0.42
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
$350K6.99N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$14.58M-$0.70N/AN/AN/AN/A-392.36%-223.78%8/8/2025 (Estimated)
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$14.29M-$2.37N/AN/AN/A-1,029.50%-57.86%-47.94%8/11/2025 (Estimated)
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$12.51M-$2.90N/AN/AN/AN/A21.32%16.39%8/8/2025 (Estimated)
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/A-$1.55N/AN/AN/AN/AN/AN/A

Latest PTN, ACXP, KPRX, and APRE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million
5/12/2025Q1 2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.14-$0.11+$0.03-$0.11N/AN/A
5/9/2025Q1 2025
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$0.77-$0.52+$0.25-$0.52$0.75 millionN/A
3/25/2025Q4 2024
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.69-$0.49+$0.20-$0.49$0.15 million$0.21 million
3/25/2025Q4 2024
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$0.64-$1.04-$0.40-$1.04$0.75 million$0.75 million
3/17/2025Q4 2024
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.18-$0.16+$0.02-$0.16N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/AN/A
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/AN/AN/AN/AN/A
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/A
1.80
1.80
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
7.28
7.28
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/A
8.97
8.97
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
11.53%
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
76.97%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
11.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
323.48 million11.99 millionOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
75.53 million4.74 millionNo Data
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
103.04 million2.97 millionNot Optionable
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
3026.01 millionN/AN/A

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acurx Pharmaceuticals stock logo

Acurx Pharmaceuticals NASDAQ:ACXP

$0.39 0.00 (-0.26%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$1.80 +0.08 (+4.34%)
Closing price 03:59 PM Eastern
Extended Trading
$1.80 0.00 (-0.28%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Kiora Pharmaceuticals stock logo

Kiora Pharmaceuticals NASDAQ:KPRX

$3.04 +0.04 (+1.17%)
Closing price 03:58 PM Eastern
Extended Trading
$3.05 +0.01 (+0.46%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Palatin Technologies stock logo

Palatin Technologies NYSE:PTN

$0.09 -0.08 (-44.65%)
As of 05/7/2025

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.